Could US FDA User Fee Bill Include The Long-Sought 505(b)(2) Pathway For Biosimilars?

 
• By Derrick Gingery
  
Road construction
Congress could consider creating a 505(b)(2)-like pathway for biosimilars in upcoming FDA-focused legislation • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products